Brodil

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Brodil

Quick Facts

Property Description
Active Ingredient Salbutamol (INN) / Albuterol (USAN)
Pharmacological Class Short-Acting Beta-2 Adrenergic Agonist (SABA)
General Purpose Rapid bronchodilation (airway widening)
Primary Forms Inhaler solution, pressurized inhaler, tablet, syrup
Origin Synthetic organic compound

Brodil is a pharmaceutical preparation whose primary active component is Salbutamol, a synthetic organic compound classified as a Short-Acting Beta-2 Adrenergic Agonist (SABA). This medication is fundamentally an effective, fast-acting bronchodilator designed to quickly relieve acute episodes of obstructed breathing.

Brodil: Definition and Classification as a Bronchodilator

Brodil belongs to the pharmacological class known as sympathomimetic agents, which selectively target the beta2-adrenoceptors. The active substance, Salbutamol (known as Albuterol in the US), is widely utilized as a primary agent for conditions involving reversible airways obstruction. This therapeutic role is clinically recognized.

Its classification as a SABA defines its rapid onset and limited duration of action, distinguishing it from Long-Acting Beta Agonists (LABAs) which are reserved for baseline, preventative control rather than acute relief.

Composition and Available Forms of Salbutamol

The core of Brodil is the active ingredient, Salbutamol or its sulfate salt, which is often manufactured as a racemic mixture. This substance is formulated for various modes of delivery, with the most common dosage forms being solutions for inhalation via a nebulizer or a pressurized metered-dose inhaler. Oral preparations, such as the Tablet and Syrup, are also available for different routes of administration, sometimes specifically positioned for pediatric groups. While Brodil is primarily a single-ingredient product, certain formulations may be marketed as combination products to include other active entities, such as mucolytics or expectorants.

General Purpose: The Core Benefit of Airway Widening

The general purpose of Brodil is to provide quick, effective relief for tightness in the chest by facilitating the widening of the air passages. The medication achieves this by causing the immediate and targeted relaxation of the bronchial smooth muscle surrounding the air tubes. This rapid action, known as bronchodilation, is the central benefit, ensuring the drug can quickly reverse the physical narrowing that impedes air movement into and out of the lungs. For example, it is typically used in a scenario where sudden shortness of breath requires a rapid restoration of normal air flow.

What side effects are possible with Brodil?

Possible Side Effects and Safety Information

The safety profile of Brodil is primarily determined by its beta2-agonist component, which can lead to cardiovascular and central nervous system effects, alongside the risks associated with the mucolytic component.

Adverse Reactions

Classification System-Organ Class Involved Examples of Adverse Reactions (Common/Frequent)
Common Nervous System / Musculoskeletal Fine tremor (especially of the hands), headache, muscle cramps, dizziness, nervousness.
Common Cardiac Disorders Palpitations, increased heart rate.
Less Common Gastrointestinal Nausea, vomiting, dryness of mouth/throat, gastrointestinal disturbances.

Serious and Clinically Significant Safety Concerns

  • Hypokalemia: Potentially serious decreases in serum potassium levels may occur with beta2-agonist therapy, which can be exacerbated by concomitant use with diuretics, steroids, or xanthine derivatives, and by hypoxia in acute severe asthma.
  • Cardiovascular Effects: The medication should be used with caution in patients with pre-existing cardiovascular disorders, including coronary insufficiency, cardiac arrhythmias, and hypertension, due to the potential for clinically significant effects on pulse rate and blood pressure.
  • Severe Reactions: Rare reports exist of Hypersensitivity (including angioedema and anaphylaxis) and Severe Cutaneous Adverse Reactions (SCARs) such as Stevens-Johnson syndrome and toxic epidermal necrolysis, associated with the mucolytic component (ambroxol/bromhexine). Treatment must be immediately discontinued if signs of a progressive skin rash or hypersensitivity reaction appear.
  • Paradoxical Bronchospasm: Like other inhalation therapies, Brodil has the potential to cause paradoxical bronchospasm, which is life-threatening and requires immediate discontinuation of the product.

Population-Specific Safety Considerations

  • Contraindications: Brodil is contraindicated in patients with a history of hypersensitivity to its components, history of gastric ulceration, history of Stevens-Johnson syndrome, and threatened abortion in the first or second trimesters of pregnancy.
  • Pre-existing Conditions: Caution is advised in patients with diabetes mellitus (due to potential alteration of blood glucose levels), hyperthyroidism, glaucoma, and seizure disorders.
  • Pregnancy and Lactation: Use during pregnancy and lactation should only be considered if the expected clinical benefit outweighs the potential risk to the fetus or infant, as the drug's components are known to cross the placental barrier or be secreted in breast milk.

Overdosage is typically associated with exacerbated beta2-agonist effects, including severe tremor, tachycardia, nervousness, headache, and hypokalaemia.

Overdose and Emergency Response

Overdose and When to Seek Help

Official regulatory documents describe that overdose with Brodil (Salbutamol/Albuterol) results in an exaggeration of its pharmacologic effects, which can be fatal and requires immediate medical attention. Excessive use of inhaled sympathomimetics has been associated with reported fatalities.

Documented Overdose Manifestations

System Official Regulatory Statement
Cardiovascular Tachycardia, Palpitations, and Cardiac Arrhythmias.
Metabolic Hypokalaemia (low serum potassium), Lactic Acidosis, and Hyperglycaemia (high blood glucose).
Neurological Tremor, Headache, CNS Stimulation, and Seizure.

Regulator-Mandated Emergency Actions

Suspected overdose necessitates immediate intervention. Regulatory labeling explicitly instructs individuals to seek immediate medical attention or call the Poison Help line at once. These actions are mandated because serious metabolic complications, such as hypokalaemia and lactic acidosis, may occur and require urgent management.

Supportive Measures

Treatment is primarily symptomatic therapy. Serum potassium levels should be monitored due to the potential for hypokalaemia. In cases of overdose, a cardioselective beta-blocking agent may be considered by healthcare professionals as a countermeasure, although its use is cautioned in patients with a history of bronchospasm. Nausea and vomiting, particularly with oral overdose, have been reported predominantly in children.

Therapeutic Uses of Brodil

The medication is commonly used across conditions presenting with acute episodes of respiratory distress, and may assist with maintaining functional stability when symptoms interfere with routine activities. Brodil is relevant for easing symptoms associated with major lung diseases.

Acute Management of Asthma and COPD Symptoms

Brodil is applied in clinical settings that involve acute or unstable symptom patterns related to reversible obstructive airway disease, such as asthma and COPD (including chronic bronchitis and emphysema). The medication is used for managing symptom clusters that may become intense or disruptive, specifically wheezing, chest tightness, and acute shortness of breath. It contributes to improved comfort during periods of heightened symptoms and may assist with maintaining a sense of stability when symptoms are more noticeable.

Relief of Episodic and Trigger-Induced Distress

The medicine is relevant for easing recurrent or episodic manifestations, commonly used when short-term symptomatic assistance is needed when symptoms appear suddenly or fluctuate. It is also generally applied to help prevent breathing difficulties that may be caused by exercise or exposure to known environmental irritants. This application supports the patient during difficult episodes by easing anticipated distress and assists with maintaining functional stability.


Quick Fact: Relief for Acute Bronchospasm Brodil is commonly used when short-term symptomatic assistance is needed for acute or temporary symptom exacerbations. It is relevant in contexts involving heightened systemic burden that interfere with functional stability.

Regulatory References

  1. NIH MedlinePlus overview

Eligibility and Restrictions for Use

Who Can and Cannot Use Brodil?

Brodil is a medication typically used to manage conditions with productive cough and bronchospasm, often containing a combination of bronchodilators (e.g., salbutamol, levosalbutamol, terbutaline) and mucolytics/expectorants (e.g., ambroxol, guaifenesin, bromhexine). The specific components dictate precise usage, but general cautions apply.

Contraindications (Who Should Not Use Brodil)

Brodil is generally not recommended for individuals with a known hypersensitivity or allergy to any of its active components or inactive ingredients. Depending on the formulation, it may also be contraindicated for patients with a history of gastric ulceration due to the potential for gastrointestinal irritation, or a history of Stevens-Johnson syndrome.

Cautionary Use (Consult Your Doctor)

Many patients require careful medical evaluation before using Brodil. This is especially true for individuals with pre-existing conditions such as cardiovascular disorders (e.g., coronary insufficiency, hypertension, or cardiac arrhythmias), hyperthyroidism, diabetes mellitus, seizure disorders, glaucoma, or significant liver or kidney impairment. Brodil should also not be used concurrently with cough suppressants, as they may counteract the intended effect, or with certain medications like beta-blockers, tricyclic antidepressants, or MAO inhibitors.

Patient Group Recommendation
Pregnancy/Breastfeeding Use only if potential benefit outweighs risk; consult a healthcare provider.
Children Generally not recommended for children under two years of age, and used with caution in children under six.
Older Patients Use with caution and medical supervision, especially with coexisting liver/kidney issues.

Always disclose your complete medical history and current medications to your healthcare provider to ensure Brodil is appropriate and safe for your specific health needs.

What should I know about interactions with other medicines?

Interactions with other medicines and products

This section summarizes interaction patterns for Brodil (Salbutamol) as officially documented in government regulatory labeling.

Contraindicated and Restricted Combinations

Co-administration with beta-adrenergic receptor blocking agents is officially contraindicated, as these agents can antagonize the pulmonary effect of Brodil and may induce severe bronchospasm. Concomitant use with other short-acting sympathomimetic aerosol bronchodilators is restricted due to the potential for harmful cardiovascular additive effects.

Pharmacodynamic and Metabolic Interactions

Several drug classes present a documented risk of pharmacodynamic reinforcement or metabolic imbalance when co-administered:

  • Monoamine Oxidase Inhibitors (MAOIs) and Tricyclic Antidepressants (TCAs): Use requires extreme caution, as the cardiovascular effects of Brodil may be potentiated. Cautionary rules state this applies to patients currently treated with, or within two weeks of discontinuing, these agents.
  • Diuretics, Xanthine Derivatives, and Corticosteroids: Co-administration may potentiate the risk of hypokalemia (low potassium levels). Official labeling advises that serum potassium levels should be monitored, particularly in patients with severe airway obstruction who are receiving multiple agents that induce this effect.

Altered Drug Exposure

Official studies have documented that co-administration of Brodil may result in a notable mean decrease in serum levels of Cardiac Glycosides (e.g., Digoxin). Regarding non-medicinal substances, there is insufficient official data to confirm the safety of combining Brodil with herbal remedies or supplements as specific interaction testing is generally not available.


This profile is based strictly on label-mandated restrictions, monitoring requirements, and documented physiological effects of co-administration.

Mechanism of Action

Targeted beta2-Adrenoceptor Agonism and Airway Relaxation

The drug initiates its effect by acting as a selective agonist on the beta2-Adrenoceptors (beta2-ARs), which are primarily located on the smooth muscle cells surrounding the bronchial tubes. This targeted interaction mimics the body's natural signaling molecules, functionally activating the receptors to initiate the sequence that leads to the physiological event of bronchial smooth muscle relaxation.

The Intracellular cAMP Signaling Cascade

Receptor activation triggers the G s-protein and the enzyme Adenylyl Cyclase, which increases the concentration of the intracellular messenger cyclic AMP ( cAMP). Elevated cAMP levels modulate key enzymes (PKA) that ultimately prevent the interaction of the muscle's contractile proteins (actin and myosin), thereby suppressing the mechanism required for muscle shortening and leading to the physiological consequence of bronchodilation.

Mechanism Constraints: Receptor Regulation

The resulting physiological action is subject to the cell's own regulatory feedback. Prolonged or excessive stimulation can cause beta2-AR desensitization and down-regulation, a process where the target receptors become less responsive or fewer in number. This limitation directly impacts the magnitude of the physiological response, reducing the ability to sustain the resulting smooth muscle relaxation.

Dosage and Administration Information

Administration Scope and Official Dosing Guidelines

Brodil (Salbutamol/Albuterol) is intended for use within a strictly defined, short-acting administration protocol. The medication is approved for administration via oral inhalation (using pressurized inhalers or nebulizer solutions), oral ingestion (tablet and syrup forms), and parenteral injection (IV, IM, SC) routes.

Dosing and Frequency

The standard protocol for the relief of acute symptoms via inhalation involves taking 2 inhalations (180 --200 mu g total), which may be repeated as needed every 4 to 6 hours. For prevention of breathing difficulty related to exercise, 2 inhalations are taken 15 to 30 minutes prior to activity. Oral maintenance regimens typically start at 4 mg three or four times daily, with specific dose adjustments for groups like older adults, who may initiate therapy at a lower dose of 2 mg.

Procedural and Usage Constraints

Correct administration requires specific steps: pressurized inhalers must be primed (by releasing test sprays) before initial use or if unused for a specified period. Oral preparations may be taken with or without food. If a scheduled oral dose is missed, instructions specify taking the next dose at the usual time, without taking two doses to compensate.

Critically, the medication is for intermittent use. The total daily intake should generally not exceed 8 inhalations for routine on-demand use. The requirement to use the inhaler more frequently than prescribed is a key usage constraint; it is considered a signal of deteriorating respiratory control and necessitates immediate medical re-evaluation, not an instruction for self-adjustment.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Brodil

Brodil's active component, Salbutamol, is the subject of extensive research, primarily evaluated in research contexts involving fluctuating or unstable symptoms. The research base includes controlled clinical trials and observational studies that contribute to understanding symptom patterns in the observed populations.

Evidence for Acute Relief of Asthma and COPD Symptoms

Researchers have conducted numerous short-term Randomized Controlled Trials (RCTs) focusing on patient groups experiencing periods of heightened symptom activity related to conditions characterized by fluctuating or episodic manifestations, such as asthma or Chronic Obstructive Pulmonary Disease (COPD). The studies monitored several key objective outcomes, including changes in lung function tests (FEV1) and patient-reported outcomes describing perceived discomfort. Findings describe patterns observed in the studies over the immediate hours following treatment.

A recognized research limitation is that pulmonary function outcomes apply only to the populations studied during brief observation periods. Furthermore, observational research describes patterns related to frequent use of short-acting agents like Brodil, which was observed to be associated with poor long-term outcomes in some studies. Research is ongoing to determine whether this is an indicator of underlying disease severity or a factor in itself.

Studies in Specific Patient Groups (Special Populations)

Brodil was evaluated in a wide range of populations, including adults, older adults, and various pediatric groups. However, data for certain groups remain insufficient. For instance, in infants with bronchiolitis, research exploring short-term symptom changes was observed in some studies, but the findings were mixed. The evidence quality varies across studies and the consistency of observed outcomes for this specific, very young population is still emerging.

What Is Still Uncertain About Brodil Research

The follow-up durations were limited in most trials, meaning there is limited information for long-term outcomes when Brodil is used frequently over years, which is a recognized research limitation. Furthermore, while the immediate physiological changes are explored in extensive research, the exact outcomes for very specific patient subgroups—such as infants or individuals with certain comorbid conditions—are not always clear. In general, research highlights what is known for short-term, episodic manifestations but shows that long-term functional and systemic outcomes are not fully established.

Key Studies & References

  1. Albuterol inhalation: MedlinePlus Drug Information
  2. Clinical Practice Guidelines for the Diagnosis and Management of Asthma (Used to establish standard SABA role and evidence types)
  3. Systematic reviews on inhaled $beta_2$-agonists for acute bronchiolitis in children (Represents the basis for 'mixed findings' and 'uncertainty' in special populations)

Frequently Asked Questions (FAQ)

Common questions about Brodil (FAQ)


Q: Is it true that Brodil can cause changes in sleep patterns?

A: Official regulatory labeling mentions that Brodil may cause changes in sleep patterns. Specifically, side effects such as insomnia (inability to sleep) and general 'sleep disturbances' are listed in the official product information.


Q: Can Brodil affect the results of common blood tests?

A: Official warnings from regulatory sources indicate that treatment with Brodil may affect certain markers measured in blood tests. Specifically, there is a possibility of experiencing hypokalemia (low potassium levels) or hyperglycemia (increased blood glucose).


Q: What does 'contraindication' mean in the context of Brodil?

A: A contraindication is a regulatory term that defines a condition or factor that absolutely rules out the use of a medicine. According to official documents, using Brodil when a contraindication exists could lead to an unacceptable safety risk or severe harm.


Q: What percentage of people report experiencing the most common side effects of Brodil?

A: Official documents describe the frequency of side effects using categories rather than exact numerical percentages. For example, common side effects are defined as those that affect 1 in 10 to 1 in 100 people.


Q: What are the signs of an allergic reaction to Brodil?

A: Signs of a severe allergic reaction are described in official safety information. These may include a skin rash, hives, itching, or swelling of the face, tongue, or throat. Any difficulty breathing after using Brodil should be promptly discussed with a healthcare professional.


Q: What is the significance of the box warning on Brodil's label, if any?

A: Regulatory documents contain serious warnings to ensure patient safety, even if a formal 'Box Warning' (or 'Black Box Warning') is not present. These high-level warnings highlight risks such as adverse cardiovascular events and the possibility of paradoxical bronchospasm, which is a rare but life-threatening worsening of breathing.


Q: Can Brodil make people feel dizzy or drowsy?

A: Dizziness is listed in official product information as a commonly reported side effect. Less common or rare effects include reports of drowsiness or general sleepiness.


Q: Why is it important to know who cannot use Brodil?

A: It is important to know who cannot use Brodil to ensure the drug is not used when a pre-existing condition could lead to a severe and unacceptable safety risk. Official labeling identifies these specific situations to protect patient health.


Q: Can Brodil affect a person's ability to drive or operate machinery?

A: Official regulatory data notes that specific studies on the effect of Brodil on a person's ability to drive or operate machinery have generally not been conducted. However, caution is advised because side effects such as dizziness and tremor are possible.


Q: Does Brodil have a risk of dependence or withdrawal?

A: Official clinical data has provided no indication of a risk for abuse, dependence, or withdrawal effects associated with Brodil. This conclusion is based on the data reviewed by regulatory authorities.


Q: Does Brodil have any known interactions with birth control pills?

A: Official regulatory labeling does not typically highlight a major or moderate interaction between Brodil and common hormonal birth control medications. It is generally recommended to discuss all medications being used, including hormonal contraceptives, with a healthcare professional.


Q: Can I take over-the-counter pain relievers while using Brodil?

A: Regulatory safety information does not generally list major contraindications with common over-the-counter pain relievers, such as acetaminophen or ibuprofen. For definitive guidance, the official interactions section should be consulted, and it is helpful to disclose all concurrent medications to a health professional.


Q: If I feel better, is it okay to stop taking Brodil suddenly?

A: Regulatory information indicates that changes to medication use, including stopping or increasing the frequency of use, should occur only after consulting a healthcare provider, as more frequent use may signal that the underlying condition is changing. Brodil is intended for short-term, acute relief.


Q: Does Brodil interact with alcohol?

A: Regulatory safety information generally does not identify an interaction between Brodil and alcohol.


Q: How long does Brodil stay in your system after stopping treatment?

A: Official information on the drug's activity in the body (pharmacokinetics) is available. The time it takes for the active substance to be eliminated is typically reported to be between 2.7 and 5.5 hours after administration.


Q: Are the side effects of Brodil permanent?

A: Most commonly reported side effects, such as mild tremor, restlessness, and headache, are generally considered transient. Official regulatory text implies that these effects may resolve with continued treatment or after the medicine is stopped.


Q: Is it normal for the effects of Brodil to wear off toward the end of the dosing interval?

A: Yes, the effects of Brodil are expected to wear off due to its short duration of action. According to official product information, the bronchodilator effect of a single administration of inhaled Brodil typically lasts for four to six hours, aligning with the dosing interval for acute relief.


Q: Are there specific instructions for what to do before a planned surgery when taking Brodil?

A: Official instructions state that it is important to disclose the use of Brodil to a doctor or nurse before a planned surgery. The drug may need to be stopped a specific number of hours before certain types of anesthesia are administered.


Q: Are there different brand names or generics for Brodil?

A: Yes, regulatory authorities acknowledge that the active component of Brodil, Salbutamol/Albuterol, is the key ingredient in a number of branded and generic products on the market.

How should Brodil be stored and disposed of?

Storage and Disposal Requirements for Brodil

Official regulatory documents define strict environmental and handling rules for Brodil (Salbutamol) to ensure stability and safety.


Storage Conditions

Requirement Description (Official Labeling)
Temperature Store at Controlled Room Temperature, typically 20 C to 25 C (not exceeding 30 C for syrups).
Protection Protect the product from freezing, direct light, and excessive heat; the metal canister must not be exposed to temperatures above 50 C.
Child Safety Keep the medication out of the sight and reach of children.
Container Rule The pressurized metal canister must not be punctured or thrown into fire.

Disposal Instructions

Expired or unused Brodil should be disposed of by utilizing community drug take-back programs where available. If a take-back option is not accessible, the product should be mixed with an undesirable substance (like coffee grounds) in a sealed container before discarding it in the household trash, following local regulations.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Brodil found in:

A-Z Index: